×
About 963 results

ALLMedicine™ Ca 19-9 Center

Research & Reviews  325 results

Gallbladder Cancer
http://emedicine.medscape.com/article/278641-clinica

Dec 3rd, 2021 - Practice Essentials Gallbladder cancer is a rare disease that often arises in the setting of chronic inflammation. The American Cancer Society estimates that approximatel 11,980 new cases of gallbladder cancer and cancers of nearby large bile duct...

Metabolomics Study Reveals Systematic Metabolic Dysregulation and Early Detection Marke...
https://doi.org/10.1002/ijc.33877
International Journal of Cancer; Wang S, Li M et. al.

Nov 19th, 2021 - Biomarkers for early detection of pancreatic cancer are in urgent need. To explore systematic circulating metabolites unbalance and identify potential biomarkers for pancreatic cancer in prospective Chinese cohorts, we conducted an untargeted meta...

A Randomized Study of Olaparib or Placebo in Patients With Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial
https://clinicaltrials.gov/ct2/show/NCT04858334

Nov 18th, 2021 - PRIMARY OBJECTIVE: I. To determine the relapse-free survival (RFS)-benefit from the addition of a maintenance olaparib following completion of chemotherapy in patients with resected pancreatic carcinoma and a pathogenic germline or somatic mutatio...

Co-analysis of pancreatic cyst fluid carcinoembryonic antigen and glucose with novel cu...
https://doi.org/10.1177/00045632211053998
Annals of Clinical Biochemistry; Barutcuoglu B, Oruc N et. al.

Nov 2nd, 2021 - Pancreatic cyst fluid analysis plays an important role in distinguishing between mucinous and non-mucinous cyst lesions. We aimed to compare the diagnostic performances of cyst fluid carcinoembryonic antigen (CEA), CA 19-9, and glucose in differen...

see more →

Clinicaltrials.gov  23 results

A Randomized Study of Olaparib or Placebo in Patients With Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial
https://clinicaltrials.gov/ct2/show/NCT04858334

Nov 18th, 2021 - PRIMARY OBJECTIVE: I. To determine the relapse-free survival (RFS)-benefit from the addition of a maintenance olaparib following completion of chemotherapy in patients with resected pancreatic carcinoma and a pathogenic germline or somatic mutatio...

Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
https://clinicaltrials.gov/ct2/show/NCT04812808

Oct 25th, 2021 - This study is a single-center, prospective, non-randomized trial. The population studied will consist of 10 patients of both sexes, aged 18 to 85 years, with a newly diagnosed metastatic pancreatic adenocarcinoma who will undergo palliative treatm...

Longitudinal Pancreatic Cancer Study
https://clinicaltrials.gov/ct2/show/NCT02250638

Aug 17th, 2021 - The study objectives are described below: Obtain serum and plasma specimens longitudinally collected from approximately 140 subjects diagnosed with pancreatic cancer and are about to or are currently undergoing treatment and follow-up. Specimens w...

Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT04087889

Jul 6th, 2021 - Once the eligibility is confirmed, approximately 1-3 weeks after the screening/baseline visit, the subject will return for the first infusion. Subsequent treatments will occur weekly for the first 8 infusions, followed by 4 infusion that occur 2 w...

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT04672005

Jun 10th, 2021 - Primary objective: To determine whether mFFX and mGnabP administered as a combined, alternating, front-line therapy can provide longer first line treatment for patients with metastatic pancreatic cancer, with the primary metric of time to treatmen...

see more →

News  35 results

Infigratinib Represents New Option for FGFR2+ Cholangiocarcinoma, as Efforts Shift to Target Other FGFR Alterations
https://www.onclive.com/view/infigratinib-represents-new-option-for-fgfr2-cholangiocarcinoma-as-efforts-shift-to-target-other-fgfr-alterations

Nov 9th, 2021 - Infigratinib (Truseltiq) represents a strong option for previously treated patients with locally advanced or metastatic cholangiocarcinoma whose tumors harbor FGFR2 fusions or rearrangements, according to Sameek Roychowdhury, MD, PhD, who added th...

Dr. Choti on the Role of Upfront Surgery in Pancreatic Adenocarcinoma
https://www.onclive.com/view/dr-choti-on-the-role-of-upfront-surgery-in-pancreatic-adenocarcinoma

Oct 6th, 2021 - Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses the role of upfront surgery in pancreatic adenocarcinoma. There is some controversy regarding the optimal frontline treatment for patients with pancreatic cancer....

Dr. Katz on Preoperative Chemoradiation in Localized Pancreatic Cancer
https://www.onclive.com/view/dr-katz-on-preoperative-chemoradiation-in-localized-pancreatic-cancer

Oct 6th, 2021 - Matthew H.G. Katz, MD, FACS, associate professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the role of preoperative chemoradiation for the treatment of patients with localiz...

FOLFIRINOX Should Remain Adjuvant Standard for Resectable Pancreatic Cancer
https://www.onclive.com/view/folfirinox-should-remain-adjuvant-standard-for-resectable-pancreatic-cancer

Oct 6th, 2021 - Matthew H.G. Katz, MD, FACS Systemic chemotherapy with FOLFIRINOX should be the backbone of treatment for patients with localized pancreatic cancer who have undergone surgical resection, said Matthew H.G. Katz, MD, FACS. In results of the phase ...

Sequencing After Progression on IO-Based Therapy for mGC
https://www.onclive.com/view/sequencing-after-progression-on-io-based-therapy-for-mgc

Aug 2nd, 2021 - Daniel Catenacci, MD: That may be a good transition point to getting to the next lines of therapy and what we’re looking for in terms of when we feel like the first therapies failed and when it’s time to switch. What are the symptoms? What are the...

see more →

Patient Education  2 results see all →